> Detailanzeige

Prenzler, Anne [Verfasser:in]; Yen, Linnette [Verfasser:in]; Mittendorf, Thomas [Verfasser:in]; Schulenburg, Johann-Matthias Graf von der [Verfasser:in]

Cost effectiveness of ulcerative colitis treatment in Germany: A comparison of two oral formulations of mesalazine - [published Version]

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: Sonstige Veröffentlichung; E-Artikel
  • Titel: Cost effectiveness of ulcerative colitis treatment in Germany: A comparison of two oral formulations of mesalazine
  • Beteiligte: Prenzler, Anne [Verfasser:in]; Yen, Linnette [Verfasser:in]; Mittendorf, Thomas [Verfasser:in]; Schulenburg, Johann-Matthias Graf von der [Verfasser:in]
  • Erschienen: London : BioMed Central Ltd., 2011
  • Erschienen in: BMC Health Services Research 11 (2011)
  • Ausgabe: published Version
  • Sprache: Englisch
  • DOI: https://doi.org/10.15488/575; https://doi.org/10.1186/1472-6963-11-157
  • ISSN: 1472-6963
  • Schlagwörter: mesalazine ; Colitis ; Administration ; Markov Chains ; Humans ; Asacol ; drug dosage form ; cost benefit analysis ; Ulcerative ; Cost-Benefit Analysis ; cost analysis ; Anti-Inflammatory Agents ; cost effectiveness ; Costs and Cost Analysis ; Mesalamine ; nonsteroid antiinflammatory agent ; Dosage Forms ; comparative study ; cost ; Mezavant ; human ; Oral ; Ulcerative colitis ; Non-Steroidal ; [...]
  • Entstehung:
  • Anmerkungen: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Beschreibung: Background: The treatment of ulcerative colitis (UC) can place a substantial financial burden on healthcare systems. The anti-inflammatory compound 5-aminosalicylic acid (5-ASA; mesalazine) is the recommended first-line treatment for patients with UC. In this analysis, the incremental cost effectiveness ratio (ICER) of two oral formulations of 5-ASA (Mezavant and Asacol) is examined in the treatment of patients with mild-to-moderate, active UC in Germany. Methods. A Markov cohort model was developed to assess the cost effectiveness of Mezavant compared with Asacol over a 5-year period in the German Statutory Health Insurance (SHI). Drug pricing details for 2009 were applied throughout the model, and overall resource use was determined and also fitted to 2009 from published results of a large cross sectional study of German SHI patients. Cost per quality adjusted life year (QALY) was the primary endpoint for this study. Remission rates were obtained using data from a randomised, phase III trial of Mezavant with an active Asacol reference arm and a long-term, open label, safety and tolerability trial of Mezavant. Uncertainty in the study model was assessed using one-way and probabilistic sensitivity analyses applying a Monte Carlo simulation. Results: Over a 5-year period, healthcare costs for patients receiving Mezavant were 624 Euro lower than for patients receiving Asacol. Additionally, patients receiving Mezavant gained 0.011 QALYs or 18 more days in remission compared with Asacol. One-way sensitivity analyses suggest that these results are driven by both differences in the acquisition cost between mesalazine formulations and differences in treatment efficacy. Furthermore, sensitivity analyses suggest a probability of 76% for cost savings and higher QALYs with Mezavant compared with Asacol. If adherence and its influence on the remission rates and the risk of developing colorectal cancer were included in the model, the results might have even been more favorable to Mezavant due to its once daily dosing ...
  • Zugangsstatus: Freier Zugang